DiagnoCure Inc.
DiagnoCure Inc. company was founded in 1994 and is headquartered in Quebec City, Canada. DiagnoCure, Inc., a life sciences company, engages in the research, development, production, and commercialization of diagnostic tests for the detection and management of cancers in Canada. It focuses on colon, prostate, breast, and lung cancers. The company provides ImmunoCyt /uCyt+, a tool for the diagnosis and monitoring of bladder cancer; uPM3, a noninvasive test for the detection of prostate cancer; and molecular diagnostic tests for lung cancer. It also offers Previstage GCC colorectal cancer staging test for the management of colorectal cancer. The company holds worldwide diagnostic and therapeutic rights for the use of the PCA3 technology in prostate cancer diagnosis. DiagnoCure has a strategic alliance with Gen-Probe Incorporated for the development and commercialization of diagnostic products using the DiagnoCure PCA3 gene technology for prostate cancer.
Contact Details
Executives
President and CEO
John C. Schafer
VP Marketing and National Sales
Phillip Wells